UCrest Bhd (XKLS:0005) EBIT: RM0.29 Mil (TTM As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is UCrest Bhd EBIT?

UCrest Bhd XKLS:0005 EBIT is RM0.29 Mil as of May. 2026. The stock has 3 warning signs investors should review.

UCrest Bhd's earnings before interest and taxes (EBIT) for the three months ended in May. 2026 was RM-0.61 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in May. 2026 was RM0.29 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. UCrest Bhd's annualized ROC % for the quarter that ended in May. 2026 was -8.05%. UCrest Bhd's annualized ROC (Joel Greenblatt) % for the quarter that ended in May. 2026 was -14.36%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. UCrest Bhd's Earnings Yield (Joel Greenblatt) % for the quarter that ended in May. 2026 was 0.74%.

UCrest Bhd  (XKLS:0005) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

UCrest Bhd's annualized ROC % for the quarter that ended in May. 2026 is calculated as:

ROC % (Q: May. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Feb. 2026 ) + Invested Capital (Q: May. 2026 ))/ count )
=-2.616 * ( 1 - 0% )/( (31.945 + 33.009)/ 2 )
=-2.616/32.477
=-8.05 %

where

Invested Capital(Q: Feb. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=46.635 - 4.39 - ( 10.3 - max(0, 4.783 - 30.066+10.3))
=31.945

Invested Capital(Q: May. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=47.669 - 5.35 - ( 9.31 - max(0, 5.703 - 32.812+9.31))
=33.009

Note: The Operating Income data used here is four times the quarterly (May. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

UCrest Bhd's annualized ROC (Joel Greenblatt) % for the quarter that ended in May. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: May. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Feb. 2026  Q: May. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2.448/( ( (0.416 + max(15.264, 0)) + (0.373 + max(18.048, 0)) )/ 2 )
=-2.448/( ( 15.68 + 18.421 )/ 2 )
=-2.448/17.0505
=-14.36 %

where Working Capital is:

Working Capital(Q: Feb. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(19.188 + 0.043 + 0.423) - (4.39 + 0 + 8.8817841970013E-16)
=15.264

Working Capital(Q: May. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(22.915 + 0.043 + 0.44) - (5.35 + 0 + 8.8817841970013E-16)
=18.048

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (May. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

UCrest Bhd's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: May. 2026 )
=0.291/39.392
=0.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCrest Bhd EBIT Related Terms

UCrest Bhd EBIT Historical Data

* Premium members only.

The historical data trend for UCrest Bhd's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCrest Bhd EBIT Chart

UCrest Bhd Annual Data
Trend May17 May18 May19 May20 May21 May22 May23 May24 May25 May26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -35.03 0.20 4.20 5.17 0.29

UCrest Bhd Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.67 1.12 0.58 -0.79 -0.61

XKLS:0005 vs VEEV, BTSG, HQY: EBIT Comparison

For the Health Information Services subindustry, UCrest Bhd's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UCrest Bhd EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, UCrest Bhd's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where UCrest Bhd's EV-to-EBIT falls into.


UCrest Bhd EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of RM0.29 Mil mean?
UCrest Bhd (XKLS:0005) has a EBIT of RM0.29 Mil as of May. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on UCrest Bhd.
Is UCrest Bhd's EBIT too high?
UCrest Bhd's current EBIT is RM0.29 Mil.
How does UCrest Bhd's EBIT compare to VEEV and BTSG?
UCrest Bhd's EBIT of RM0.29 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on UCrest Bhd. UCrest Bhd's current EBIT is RM0.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCrest Bhd stock overvalued right now?
Based on GuruFocus' analysis, UCrest Bhd (XKLS:0005) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.08, compared to a current price of RM0.07 — trading 18.8% below its estimated fair value. The current EBIT is RM0.29 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For UCrest Bhd (XKLS:0005), the current EBIT is RM0.29 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

UCrest Bhd Business Description

Address 8, First Avenue, Bandar Utama, 6th Floor, Unit 4, Petaling Jaya, SGR, MYS, 47800
UCrest Bhd is a technology provider company that engages in network design, product development, and software development. The firm provider of Cloud Hospital and mobile health services. The company offers an i-Medic platform for diagnosis, management, and treatment of chronic diseases such as cardiovascular diseases (CVD), cancer, diabetes, hypertension, sleep apnea, stroke rehabilitation, and other diseases.